文献速递重症综合管理与镇静镇痛心脑血管急症

静脉左甲状腺素用于血流动力学不稳定的脑死亡心脏供者

Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors.
PubMed 文献 · N Engl J Med · 2023-01-01
一句话结论在血流动力学不稳定的脑死亡潜在心脏供者中,静脉输注左甲状腺素并未较生理盐水显著增加心脏移植数量(54.9% vs 53.2%,校正RR 1.01,P=0.57)。

该试验纳入美国15个器官获取组织的852例脑死亡供者,随机分为静脉左甲状腺素组(30 μg/h,至少12小时)或生理盐水安慰剂组。主要终点心脏移植率在左甲状腺素组为54.9%,生理盐水组为53.2%(校正RR 1.01;95%CI 0.97-1.07;P=0.57),无显著差异。移植后30天移植物存活率分别为97.4%和95.5%(差值1.9个百分点;95%CI -2.3至6.0;非劣效性P<0.001,界值6个百分点)。左甲状腺素组严重高血压和心动过速病例更多。

要点

  • 在852例脑死亡供者中,左甲状腺素组心脏移植率为54.9%(230/419),生理盐水组为53.2%(223/419),校正RR 1.01(95%CI 0.97-1.07;P=0.57)。
  • 移植后30天移植物存活率:左甲状腺素组97.4%(224例),生理盐水组95.5%(213例),差值1.9个百分点(95%CI -2.3至6.0;非劣效性P<0.001,界值6个百分点)。
  • 左甲状腺素组严重高血压和心动过速病例多于生理盐水组。
  • 两组在停用血管加压药、超声心动图射血分数及每供者移植器官数量方面无实质差异。

适用人群与场景

  • 美国15个器官获取组织内,宣布脑死亡后24小时内血流动力学不稳定的潜在心脏供者。

处置流程与药物剂量

  • 左甲状腺素组:静脉输注左甲状腺素30 μg/小时,至少持续12小时;对照组输注生理盐水安慰剂。

研究设计与关键结果

  • 研究类型:随机对照试验,纳入852例脑死亡供者,其中838例纳入主要分析(左甲状腺素组419例,生理盐水组419例)。
  • 主要终点:心脏移植率左甲状腺素组54.9%(230例)vs 生理盐水组53.2%(223例),校正RR 1.01(95%CI 0.97-1.07;P=0.57)。
  • 预设受者安全性终点:移植后30天移植物存活率左甲状腺素组97.4%(224例)vs 生理盐水组95.5%(213例),差值1.9个百分点(95%CI -2.3至6.0;非劣效性P<0.001,界值6个百分点)。
  • 次要终点:停用血管加压药、超声心动图射血分数、每供者移植器官数量方面两组无实质差异;左甲状腺素组严重高血压和心动过速病例多于生理盐水组。

证据类型、等级与局限

  • 证据类型:随机对照试验;开放标签设计;由Mid-America Transplant等资助;临床试验注册号NCT04415658。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对于血流动力学不稳定的脑死亡潜在心脏供者,静脉左甲状腺素输注未较生理盐水显著增加心脏移植数量,作者结论认为不支持常规使用左甲状腺素来增加心脏移植。
  • 使用左甲状腺素时需注意严重高血压和心动过速的发生。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemodynamic instability and myocardial dysfunction are major factors preventing the transplantation of hearts from organ donors after brain death. Intravenous levothyroxine is widely used in donor care, on the basis of observational data suggesting that more organs may be transplanted from donors who receive hormonal supplementation.

METHODS: In this trial involving 15 organ-procurement organizations in the United States, we randomly assigned hemodynamically unstable potential heart donors within 24 hours after declaration of death according to neurologic criteria to open-label infusion of intravenous levothyroxine (30 μg per hour for a minimum of 12 hours) or saline placebo. The primary outcome was transplantation of the donor heart; graft survival at 30 days after transplantation was a prespecified recipient safety outcome. Secondary outcomes included weaning from vasopressor therapy, donor ejection fraction, and number of organs transplanted per donor.

RESULTS: Of the 852 brain-dead donors who underwent randomization, 838 were included in the primary analysis: 419 in the levothyroxine group and 419 in the saline group. Hearts were transplanted from 230 donors (54.9%) in the levothyroxine group and 223 (53.2%) in the saline group (adjusted risk ratio, 1.01; 95% confidence interval [CI], 0.97 to 1.07; P = 0.57). Graft survival at 30 days occurred in 224 hearts (97.4%) transplanted from donors assigned to receive levothyroxine and 213 hearts (95.5%) transplanted from donors assigned to receive saline (difference, 1.9 percentage points; 95% CI, -2.3 to 6.0; P<0.001 for noninferiority at a margin of 6 percentage points). There were no substantial between-group differences in weaning from vasopressor therapy, ejection fraction on echocardiography, or organs transplanted per donor, but more cases of severe hypertension and tachycardia occurred in the levothyroxine group than in the saline group.

CONCLUSIONS: In hemodynamically unstable brain-dead potential heart donors, intravenous levothyroxine infusion did not result in significantly more hearts being transplanted than saline infusion. (Funded by Mid-America Transplant and others; ClinicalTrials.gov number, NCT04415658.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Dhar R, Marklin GF, Klinkenberg WD, et al. Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors. N Engl J Med. 2023. PMID: 38048188. doi:10.1056/NEJMoa2305969

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。